As physicians have expressed with increasingly louder volume in the last decade, one of their primary sources of frustration continues to be the prior...
November is National Family Caregivers Month. This month serves to appreciate the role of family caregivers, address the issues they face, and further...
Maintaining, Monitoring, and Measuring a Smooth Patient Journey The journey of a rare disease patient is not an easy one from the start, frequently...
Duchenne muscular dystrophy (DMD) is a genetic, progressive form of muscular dystrophy that occurs primarily in males. It is caused by genetic changes...
From filling out an insurance form to interpreting nutrition labels, a patient's understanding of what they're reading and ability to use that...
The definition of a specialty drug continues to evolve as the specialty drug pipeline advances and expands. Specialty pharmaceuticals (specialty drugs)...
A specialty pharmacy must be able to have seamless collaboration and communication with the pharmaceutical manufacturer’s hub. In a recent manufacturer...
Alzheimer’s disease is the most common type of dementia. It is an irreversible, degenerative brain disorder that slowly destroys memory, language,...
When a pharmaceutical manufacturer or a payor is choosing a specialty pharmacy partner, there are many important aspects to consider and expectations...
In the U.S., it is estimated that 25-30 million people, almost 10% of the population, have rare diseases. While there are approximately 7,000 rare...
Orsini is a leading independent national specialty pharmacy accredited by ACHC, JCAHO, URAC, and VIPPS. The services we provide allow patients, physicians, payors, and manufacturers to improve care, simplify processes, and achieve better outcomes.
Now In Stock: ADZYNMA (ADAMTS13, recombinant-krhn), for patients with cTTP
Orsini Specialty Pharmacy Selected as Distribution Partner for Adzynma (ADAMTS13, recombinant-krhn), a Newly Approved Treatment for an Ultra-Rare Blood Clotting Disorder
Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
Orsini Specialty Pharmacy Names Darin DeCarlo Chief Growth Officer
Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease
.jpg?width=1754&height=637&name=SP_Logo_Color_RGB%202020update%20(1).jpg "Orsini Specialty Pharmacy Logo"){kind=logo}
![[Whitepaper] Payor Considerations When Choosing a Specialty Pharmacy](https://no-cache.hubspot.com/cta/default/7642930/d6329582-47a1-404d-b2a8-63c2637a9807.png)